Inclisiran

Novartis announced the FDA approved inclisiran, its small-interfering RNA therapy for LDL lowering.

In an update on FDA approvals and late-breaking trials in lipid therapies, a speaker reviewed the current and future landscapes of LDL- and triglyceride-lowering therapies.

The National Lipid Association Scientific Sessions, a hybrid meeting held Sept. 24-26, 2021, will include four featured sessions, updates on NLA scientific statements and numerous abstract presentations.